Francesco Costa

Francesco Costa is an Associate Professor of Practice in Government, Health & Not for Profit at SDA Bocconi School of Management. Francesco’s collaboration with SDA Bocconi started in 2012. He has gradually widened his scope of research and teaching, starting from the Cergas (Centro di Ricerche sulla Gestione dell'Assistenza Sanitaria e Sociale) Pharmaceutical Observatory and including, over time, other research areas related to health economics, Health Technology Assessment and Market Access. He has directed a number of courses for employees of companies from the pharmaceutical and medical device sector and several sponsored educational programs dedicated to physicians, pharmacists and other healthcare and public sector professionals. Since 2018 Francesco has coordinated the executive open program in Patient Access & Government Affairs: Value-Based Market Access. Moreover his teaching also includes «Pharmaceutical Policy» at the SDA Bocconi full time master program in healthcare management (MiMS).

His current research activity is focused on three themes: 1) economic evaluations of healthcare technologies (cost-effectiveness, cost-utility and budget impact analysis); 2) analysis of health technology markets in terms of performance, innovation and reaction to public policies; 3) Market and Patient Access. He has published several articles in international peer-reviewed journals and he is the author of a number of chapters in monographic works. Since 2015 he has authored the chapter on healthcare expenditure in the OASI (Osservatorio sulle Aziende e sul Sistema Sanitario Italiano) report, the leading annual Italian publication on issues related to the healthcare system .

Francesco has published serveral articles in «Il Sole 24 Ore Sanità» and is the author of a book on the management and organization of clinical trials. As an expert, he is often involved in advisory boards for companies operating in the pharmaceutical / medical devices industry. Before starting its career at SDA Bocconi he worked for two multinational pharma corporations in the Market Access and New Business Developmentn functions.

Francesco holds an MSc in Healthcare Management at SDA Bocconi and a PhD in Morphological Sciences at Università degli Studi di Milano. He graduated in Medical biotechnology from Università degli Studi di Milano.

Teaching domains

• Market/Patient Access Management
• HTA Governance Systems
• Health Technology Assessment
• Pharmaceutical and Other Medical Technologies Markets
• Public Affairs Management

Latest publications

• ARMENI P., BERTOLANI A., BORSOI L., COSTA F.
  La spesa sanitaria: composizione ed evoluzione in Rapporto OASI 2021
  CERGAS (Eds),Egea, chap. 3, pp.117-173, 2021
  
• TARRICONE R., AMATUCCI F., ARMENI P., BANKS H., BORSOI L., CALLEA G., CIANI O., COSTA F., FEDERICI C. B., TORBICA A., MARLETTA M.
  Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies
  Health Policy, 2021, vol.125, no. 5, pp.602-608
  
• JOMMI C., ARMENI P., BERTOLANI A., COSTA F., OTTO M.
  The future of Funds for Innovative Medicines: results from a Delphi Study
  Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2021, vol.8, pp.22-28
  
• ARMENI P., BORSOI L., FORNARO G., JOMMI C., COLOMBO N., COSTA F.
  Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service
  Clinical Therapeutics, 2020, vol.42, no. 7, pp.1192-1209
  
• ARMENI P., BORSOI L., FORNARO G., JOMMI C., GROSSI F., COSTA F.
  Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service
  Clinical Therapeutics, 2020, vol.42, no. 5, pp.830-847
  
• JOMMI C., ARMENI P., COSTA F., BERTOLANI A., OTTO M.
  Implementation of Value-based Pricing for Medicines
  Clinical Therapeutics, 2020, vol.42, no. 1, pp.15-24